Cold atmospheric plasma induced genotoxicity and cytotoxicity in esophageal cancer cells

Estarabadi, Hanieh; Atyabi, Seyed Alireza; Tavakkoli, Sajjad; Noormohammadi, Zahra; Gholami, Mohammad Reza; Ghiaseddin, Ali; Irani, Shiva

doi:10.1007/s11033-021-06178-3

Cited by 6 publications

(7 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tumor cells happen to be mostly in the S phase due to their dividing nature. These results confirm that CAP induces DNA damage, particularly in cancer cells ( 32 , 66 ).…”

Section: Cap’s Treatment For Head and Neck Upper Aerodigestive Tract ...supporting

confidence: 81%

Plasma oncology: Adjuvant therapy for head and neck cancer using cold atmospheric plasma

Rui

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

The worldwide incidence of head and neck cancer (HNC) exceeds half a million cases annually, and up to half of the patients with HNC present with advanced disease. Surgical resection remains the mainstay of treatment for many HNCs, although radiation therapy, chemotherapy, targeted therapy, and immunotherapy might contribute to individual patient’s treatment plan. Irrespective of which modality is chosen, disease prognosis remains suboptimal, especially for higher staging tumors. Cold atmospheric plasma (CAP) has recently demonstrated a substantial anti-tumor effect. After a thorough literature search, we provide a comprehensive review depicting the oncological potential of CAP in HNC treatment. We discovered that CAP applies to almost all categories of HNC, including upper aerodigestive tract cancers, head and neck glandular cancers and skin cancers. In addition, CAP is truly versatile, as it can be applied not only directly for superficial or luminal tumors but also indirectly for deep solid organ tumors. Most importantly, CAP can work collaboratively with existing clinical oncotherapies with synergistic effect. After our attempts to elaborate the conceivable molecular mechanism of CAP’s anti-neoplastic effect for HNC, we provide a brief synopsis of recent clinical and preclinical trials emphasizing CAP’s applicability in head and neck oncology. In conclusion, we have enunciated our vision of plasma oncology using CAP for near future HNC treatment.

show abstract

“…Tumor cells happen to be mostly in the S phase due to their dividing nature. These results confirm that CAP induces DNA damage, particularly in cancer cells ( 32 , 66 ).…”

Section: Cap’s Treatment For Head and Neck Upper Aerodigestive Tract ...supporting

confidence: 81%

Plasma oncology: Adjuvant therapy for head and neck cancer using cold atmospheric plasma

Rui

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“… Yang et al (2020) demonstrated that CAP-activated solution induces apoptotic signaling in basal cell carcinoma cells, and that this effect was associated with the activation of the MAPK signaling pathway. Finally, Estarabadi et al (2021) found that both direct and indirect CAP treatment could not only induce cytotoxicity by shifting Bax/Bcl-2 towards apoptosis, but also cause genotoxicity in oesophageal cancer cells. Although there has been research reporting that synergistic treatment using CAP and silymarin nanoemulsion could inhibit melanoma tumorigenesis via targeting HGF/c-MET downstream pathway ( Adhikari et al, 2019 ), our discussion here is limited to standalone CAP treatment.…”

Section: Discussionmentioning

confidence: 99%

Cold atmospheric plasma induces apoptosis in human colon and lung cancer cells through modulating mitochondrial pathway

Wang

Mang

et al. 2022

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Cold atmospheric plasma (CAP) is an emerging and promising oncotherapy with considerable potential and advantages that traditional treatment modalities lack. The objective of this study was to investigate the effect and mechanism of plasma-inhibited proliferation and plasma-induced apoptosis on human lung cancer and colon cancer cells in vitro and in vivo. Piezobrush® PZ2, a handheld CAP unit based on the piezoelectric direct discharge technology, was used to generate and deliver non-thermal plasma. Firstly, CAPPZ2 treatment inhibited the proliferation of HT29 colorectal cancer cells and A549 lung cancer cells using CCK8 assay, caused morphological changes at the cellular and subcellular levels using transmission electron microscopy, and suppressed both types of tumor cell migration and invasion using the Transwell migration and Matrigel invasion assay. Secondly, we confirmed plasma-induced apoptosis in the HT29 and A549 cells using the AO/EB staining coupled with flow cytometry, and verified the production of apoptosis-related proteins, such as cytochrome c, PARP, cleaved caspase-3 and caspase-9, Bcl-2 and Bax, using western blotting. Finally, the aforementioned in vitro results were tested in vivo using cell-derived xenograft mouse models, and the anticancer effect was confirmed and attributed to CAP-mediated apoptosis. The immunohistochemical analysis revealed that the expression of cleaved caspase-9, caspase-3, PARP and Bax were upregulated whereas that of Bcl-2 downregulated after CAP treatment. These findings collectively suggest that the activation of the mitochondrial pathway is involved during CAPPZ2-induced apoptosis of human colon and lung cancer cells in vitro and in vivo.

show abstract

“…Nevertheless, some studies have shown that cold atmospheric plasma can activate intracellular oxidative stress signals, causing DNA double-strand breaks and thus apoptosis ( 146 , 147 ). This cold-atmosphere plasma treatment method is currently used for bladder ( 148 ), cervical ( 149 ), esophageal ( 150 ), and prostate cancer ( 151 ). It effectively exerts anticancer activity and reduces host mortality rate and incidence of side effects.…”

Section: Conventional Methods Of Icd Inductionmentioning

confidence: 99%

Research progress in inducing immunogenic cell death of tumor cells

Xie

Wang

2022

Front. Immunol.

View full text Add to dashboard Cite

Immunogenic cell death (ICD) is a regulated cell death (RCD) pathway. In response to physical and chemical signals, tumor cells activate specific signaling pathways that stimulate stress responses in the endoplasmic reticulum (ER) and expose damage-associated molecular patterns (DAMPs), which promote antitumor immune responses. As a result, the tumor microenvironment is altered, and many tumor cells are killed. The ICD response in tumor cells requires inducers. These inducers can be from different sources and contribute to the development of the ICD either indirectly or directly. The combination of ICD inducers with other tumor treatments further enhances the immune response in tumor cells, and more tumor cells are killed; however, it also produces side effects of varying severity. New induction methods based on nanotechnology improve the antitumor ability and significantly reduces side effects because they can target tumor cells precisely. In this review, we introduce the characteristics and mechanisms of ICD responses in tumor cells and the DAMPs associated with ICD responses, summarize the current methods of inducing ICD response in tumor cells in five distinct categories: chemical sources, physical sources, pathogenic sources, combination therapies, and innovative therapies. At the same time, we introduce the limitations of current ICD inducers and make a summary of the use of ICD responses in clinical trials. Finally, we provide an outlook on the future of ICD inducer development and provide some constructive suggestions.

show abstract

Cold atmospheric plasma induced genotoxicity and cytotoxicity in esophageal cancer cells

Cited by 6 publications

References 57 publications

Plasma oncology: Adjuvant therapy for head and neck cancer using cold atmospheric plasma

Plasma oncology: Adjuvant therapy for head and neck cancer using cold atmospheric plasma

Cold atmospheric plasma induces apoptosis in human colon and lung cancer cells through modulating mitochondrial pathway

Research progress in inducing immunogenic cell death of tumor cells

Contact Info

Product

Resources

About